LobbyingBio-Rad Laboratories lobbying by quarter
Bio-Rad Laboratories BIO's latest lobbying report covers Q3 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $260K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Defense.
Bio-Rad LaboratoriesBIO
- Latest quarter
- $20K
- Q3 2026 · 1 reports
- Last 12 months
- $260K
- Last 4 quarters
- vs last quarter
- −75.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $80K | 1 |
| Q1 2023 | $80K | 1 |
| Q2 2023 | $80K | 1 |
| Q3 2023 | $80K | 1 |
| Q4 2023 | $80K | 1 |
| Q1 2024 | $80K | 1 |
| Q2 2024 | $80K | 1 |
| Q3 2024 | $80K | 1 |
| Q4 2024 | $80K | 1 |
| Q1 2025 | $80K | 1 |
| Q2 2025 | $80K | 1 |
| Q3 2025 | $80K | 1 |
| Q4 2025 | $80K | 1 |
| Q1 2026 | $80K | 1 |
| Q2 2026 | $80K | 1 |
| Q3 2026 | $20K | 1 |
By issue
- Health issues$673.3K · 16 reports
- Defense$433.3K · 13 reports
- Medicare and Medicaid$113.3K · 5 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Health & Human Services, Dept of (HHS)16 reports
- HOUSE OF REPRESENTATIVES16 reports
- SENATE16 reports
- Centers For Medicare and Medicaid Services (CMS)5 reports
Firms it paid
| Firm | ||
|---|---|---|
| Forbes-Tate | $1.2M | 16 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SAMANTHA MCLEAN | Senior LA, Senator Cruz (2018-2023); LA, Senator Cruz (2016-2018); Leg Aid, Senator Cruz (2013-2016); Assistant to the CoS and LD, Senator Cruz (2013-2013); SA, Senator DeMint (2012-2012) | Q3 2023 |
| RACHEL MILLER | Legislative Assistant, Sen. Dianne Feinstein (2003-2007); Legislative Assistant, Rep. Eliot Engel (2000-2003) | Q1 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 09/02for Q3 | Forbes-Tate | $20K |
| 07/20for Q2 | Forbes-Tate | $80K |
| 04/17for Q1 | Forbes-Tate | $80K |
| 01/18for Q4 2025 | Forbes-Tate | $80K |
| 25/10/19for Q3 2025 | Forbes-Tate | $80K |
| 25/07/18for Q2 2025 | Forbes-Tate | $80K |
| 25/04/17for Q1 2025 | Forbes-Tate | $80K |
| 25/01/17for Q4 2024 | Forbes-Tate | $80K |
| 24/10/17for Q3 2024 | Forbes-Tate | $80K |
| 24/07/14for Q2 2024 | Forbes-Tate | $80K |
| 24/04/12for Q1 2024 | Forbes-Tate | $80K |
| 24/01/16for Q4 2023 | Forbes-Tate | $80K |
| 23/10/18for Q3 2023 | Forbes-Tate | $80K |
| 23/07/16for Q2 2023 | Forbes-Tate | $80K |
| 23/04/17for Q1 2023 | Forbes-Tate | $80K |
| 23/01/15for Q4 2022 | Forbes-Tate | $80K |